Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

This study has been completed.
Sponsor:
Information provided by:
Akros Pharma Inc.
ClinicalTrials.gov Identifier:
NCT00688896
First received: May 29, 2008
Last updated: June 2, 2008
Last verified: May 2008
  Purpose

The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.


Condition Intervention Phase
Type II Hyperlipidemia
Drug: JTT-705 600 mg and pravastatin 40 mg
Drug: JTT-705 300 mg and pravastatin 40 mg
Drug: Placebo and pravastatin 40 mg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 4-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-705 (300 mg or 600 mg) Versus Placebo in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Resource links provided by NLM:


Further study details as provided by Akros Pharma Inc.:

Primary Outcome Measures:
  • % change from baseline in HDL-C; inhibition of CETP activity [ Time Frame: 4-weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • % change from baseline in LDL-C and TC/HDL-C [ Time Frame: 4-weeks ] [ Designated as safety issue: No ]
  • Plasma concentration of JTT-705 [ Time Frame: 4-weeks ] [ Designated as safety issue: No ]

Enrollment: 155
Study Start Date: June 2002
Study Completion Date: March 2004
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
JTT-705 600 mg and pravastatin 40 mg
Drug: JTT-705 600 mg and pravastatin 40 mg
  • JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
  • Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Experimental: 2
JTT-705 300 mg and pravastatin 40 mg
Drug: JTT-705 300 mg and pravastatin 40 mg
  • JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment
  • Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
  • Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime
Placebo Comparator: 3
Placebo and pravastatin 40 mg
Drug: Placebo and pravastatin 40 mg
  • Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
  • Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients having lipid values as indicated below:

    • HDL-C less than 1.6 mmol/L (60 mg/dL)
    • TG less than 4.5 mmol/L (400 mg/dL)
  • LDL more than 4.0 mmol/L (160 mg/dL)
  • Patients with CHD or CHD risk equivalent
  • Male and females between 18 and 65 years of age (female patients must be post-menopausal, surgically sterile or using an acceptable form of contraception)

Exclusion Criteria:

  • Body Mass Index of ≥ 35 kg/m2
  • Females that are pregnant or breast-feeding, and females of child bearing potential who are not using an effective method of contraception
  • Concomitant use of medications identified in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00688896

Locations
Netherlands
Amsterdam, Netherlands
Sponsors and Collaborators
Akros Pharma Inc.
  More Information

No publications provided

Responsible Party: Shoji Hoshino, DVM, Vice President, Clinical Development, Akros Pharma Inc.
ClinicalTrials.gov Identifier: NCT00688896     History of Changes
Other Study ID Numbers: AT705-X-02-001
Study First Received: May 29, 2008
Last Updated: June 2, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Hyperlipidemias
Hyperlipoproteinemia Type II
Dyslipidemias
Genetic Diseases, Inborn
Hyperlipoproteinemias
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolic Diseases
Metabolism, Inborn Errors
Dalcetrapib
Pravastatin
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014